Moreover, according to the latest National Institute on Aging – Alzheimer’s Association framework on AD (Jack et al., 2018; Cummings, 2019), a framework comprising three biomarkers β-amyloid (A), tau (T), and neurodegeneration (N) is recommended for defining the AD spectrum and for distinguishing AD from non-AD causes of cognitive impairment. This evidence concerns the gene MAPT and Cognitive impairment.